What caused IBRX's surprising EPS jump in Q3 2023?

ImmunityBio's (IBRX) unexpected positive EPS jump in Q3 2023 can be attributed to **Financial Strategic Moves and Operational Focus**: 1. **Capital Raise and Strategic Focus**: ImmunityBio's recent capital raise and strategic focus on core programs have bolstered investor confidence, as reflected in the company's stock performance and market sentiment. 2. **Cost Management**: The company's emphasis on cost management and operational efficiency likely contributed to the positive EPS surprise, indicating effective management of resources and expenses. In conclusion, ImmunityBio's Q3 2023 EPS jump was likely a result of a combination of financial strategic moves, operational focus, cost management and other undisclosed factors.